COVID-19 rapid test firm Abingdon Health signs collaboration agreement
Abingdon Health has signed a collaboration and co-marketing agreement with Abcam, a global leader in the supply of life science research tools and reagents.
The parties intend to establish a collaborative strategic relationship to enable them to identify and maximise opportunities for the provision of each party’s respective products and services, including the wider Abcam reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services.
Abingdon Health is a developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19.
Chris Yates, York-based Abingdon’s Chief Executive Officer, commented: “Abcam is a global leader in the supply of biochemical reagents, a critical component required in the manufacturing of our lateral flow tests and we are delighted to have signed this agreement with them.
"At a time when there is a shortage of such reagents in the market, this agreement secures a key supply chain for us. This will also ensure our partners and customers will have certainty of delivery when they come to us to manufacture their tests. We also look forward to working with Abcam to identify and service their customers’ lateral flow contract development and manufacturing requirements.”
Mennah Moustafa, Abcam’s VP of Business Development, commented: “We are excited to be collaborating with Abingdon Health to provide critical components for their lateral flow tests.
"As Abingdon’s source of key reagents and custom conjugation, we believe the combination of our global reach and complementary capabilities and expertise will enable more assay developers to access this core rapid diagnostic technology.
"We are looking forward to working together to enhance access and help secure long-term critical reagent supply to customers of Abingdon’s contract development and manufacturing services.”